Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890229739> ?p ?o ?g. }
- W2890229739 endingPage "517" @default.
- W2890229739 startingPage "508" @default.
- W2890229739 abstract "Eosinophils drive pathophysiology in stable and exacerbating eosinophilic asthma, and therefore treatment is focused on the reduction of eosinophil numbers. Mepolizumab, a humanized monoclonal antibody that neutralizes IL-5 and efficiently attenuates eosinophils, proved clinically effective in severe eosinophilic asthma but not in mild asthma.To study the effect of mepolizumab on virus-induced immune responses in mild asthma.Patients with mild asthma, steroid-naive and randomized for eosinophil numbers, received 750 mg mepolizumab intravenously in a placebo-controlled double-blind trial, 2 weeks after which patients were challenged with rhinovirus (RV) 16. FEV1, FVC, fractional exhaled nitric oxide, symptom scores (asthma control score), viral load (PCR), eosinophil numbers, humoral (luminex, ELISA), and cellular (flow cytometry) immune parameters in blood, BAL fluid, and sputum, before and after mepolizumab and RV16, were assessed.Mepolizumab attenuated baseline blood eosinophils and their activation, attenuated trendwise sputum eosinophils, and enhanced circulating natural killer cells. Mepolizumab did not affect FEV1, FVC, and fractional exhaled nitric oxide, neither at baseline nor after RV16. On RV16 challenge mepolizumab did not prevent eosinophil activation but did enhance local B lymphocytes and macrophages and reduce neutrophils and their activation. Mepolizumab also enhanced secretory IgA and reduced tryptase in BAL fluid. Finally, mepolizumab affected particularly RV16-induced macrophage inflammatory protein-3a, vascular endothelial growth factor-A, and IL-1RA production in BAL fluid.Mepolizumab failed to prevent activation of remaining eosinophils and changed RV16-induced immune responses in mild asthma. Although these latter effects likely are caused by attenuated eosinophil numbers, we cannot exclude a role for basophils. Clinical trial registered with www.clinicaltrials.gov (NCT 01520051)." @default.
- W2890229739 created "2018-09-27" @default.
- W2890229739 creator A5000103333 @default.
- W2890229739 creator A5013503198 @default.
- W2890229739 creator A5023335403 @default.
- W2890229739 creator A5023537666 @default.
- W2890229739 creator A5027155514 @default.
- W2890229739 creator A5038108908 @default.
- W2890229739 creator A5040330750 @default.
- W2890229739 creator A5043940021 @default.
- W2890229739 creator A5044455625 @default.
- W2890229739 creator A5051056050 @default.
- W2890229739 creator A5061580568 @default.
- W2890229739 creator A5068120833 @default.
- W2890229739 creator A5083535071 @default.
- W2890229739 creator A5091690733 @default.
- W2890229739 date "2019-02-15" @default.
- W2890229739 modified "2023-10-16" @default.
- W2890229739 title "Anti–IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study" @default.
- W2890229739 cites W1512756695 @default.
- W2890229739 cites W1970648068 @default.
- W2890229739 cites W1971505103 @default.
- W2890229739 cites W2006693860 @default.
- W2890229739 cites W2013105339 @default.
- W2890229739 cites W2016952830 @default.
- W2890229739 cites W2039710848 @default.
- W2890229739 cites W2047633306 @default.
- W2890229739 cites W2049374822 @default.
- W2890229739 cites W2050149342 @default.
- W2890229739 cites W2059522297 @default.
- W2890229739 cites W2062918919 @default.
- W2890229739 cites W2063178809 @default.
- W2890229739 cites W2090538642 @default.
- W2890229739 cites W2095263193 @default.
- W2890229739 cites W2102421434 @default.
- W2890229739 cites W2105412392 @default.
- W2890229739 cites W2106682746 @default.
- W2890229739 cites W2108236415 @default.
- W2890229739 cites W2126394283 @default.
- W2890229739 cites W2126408773 @default.
- W2890229739 cites W2154263136 @default.
- W2890229739 cites W2159168168 @default.
- W2890229739 cites W2279486260 @default.
- W2890229739 cites W2325970945 @default.
- W2890229739 cites W2341948965 @default.
- W2890229739 cites W2370552689 @default.
- W2890229739 cites W2410428723 @default.
- W2890229739 cites W2528590902 @default.
- W2890229739 cites W2607546168 @default.
- W2890229739 cites W2609112769 @default.
- W2890229739 cites W2610387541 @default.
- W2890229739 cites W2751711353 @default.
- W2890229739 doi "https://doi.org/10.1164/rccm.201803-0461oc" @default.
- W2890229739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30192638" @default.
- W2890229739 hasPublicationYear "2019" @default.
- W2890229739 type Work @default.
- W2890229739 sameAs 2890229739 @default.
- W2890229739 citedByCount "62" @default.
- W2890229739 countsByYear W28902297392019 @default.
- W2890229739 countsByYear W28902297392020 @default.
- W2890229739 countsByYear W28902297392021 @default.
- W2890229739 countsByYear W28902297392022 @default.
- W2890229739 countsByYear W28902297392023 @default.
- W2890229739 crossrefType "journal-article" @default.
- W2890229739 hasAuthorship W2890229739A5000103333 @default.
- W2890229739 hasAuthorship W2890229739A5013503198 @default.
- W2890229739 hasAuthorship W2890229739A5023335403 @default.
- W2890229739 hasAuthorship W2890229739A5023537666 @default.
- W2890229739 hasAuthorship W2890229739A5027155514 @default.
- W2890229739 hasAuthorship W2890229739A5038108908 @default.
- W2890229739 hasAuthorship W2890229739A5040330750 @default.
- W2890229739 hasAuthorship W2890229739A5043940021 @default.
- W2890229739 hasAuthorship W2890229739A5044455625 @default.
- W2890229739 hasAuthorship W2890229739A5051056050 @default.
- W2890229739 hasAuthorship W2890229739A5061580568 @default.
- W2890229739 hasAuthorship W2890229739A5068120833 @default.
- W2890229739 hasAuthorship W2890229739A5083535071 @default.
- W2890229739 hasAuthorship W2890229739A5091690733 @default.
- W2890229739 hasConcept C142724271 @default.
- W2890229739 hasConcept C203014093 @default.
- W2890229739 hasConcept C2776042228 @default.
- W2890229739 hasConcept C2776301714 @default.
- W2890229739 hasConcept C2777037409 @default.
- W2890229739 hasConcept C2777832160 @default.
- W2890229739 hasConcept C2780333948 @default.
- W2890229739 hasConcept C2781069245 @default.
- W2890229739 hasConcept C2781142857 @default.
- W2890229739 hasConcept C71924100 @default.
- W2890229739 hasConcept C88675164 @default.
- W2890229739 hasConcept C8891405 @default.
- W2890229739 hasConceptScore W2890229739C142724271 @default.
- W2890229739 hasConceptScore W2890229739C203014093 @default.
- W2890229739 hasConceptScore W2890229739C2776042228 @default.
- W2890229739 hasConceptScore W2890229739C2776301714 @default.
- W2890229739 hasConceptScore W2890229739C2777037409 @default.
- W2890229739 hasConceptScore W2890229739C2777832160 @default.
- W2890229739 hasConceptScore W2890229739C2780333948 @default.
- W2890229739 hasConceptScore W2890229739C2781069245 @default.